Summary The cytotoxicity of methotrexate (MTX) on representative human tumour cell lines (two cell lines from head and neck carcinomas, two from breast carcinomas, two from osteosarcomas and one lymphoblastoid cell line) was evaluated to: (1) examine the optimal time interval between MTX and folinic acid (FA) administration; (2) (FBS) were from Gibco (Paisley, UK). Penicillin and streptomycin were from Merieux (Lyons, France). Transferrin was from Flow Laboratories (Irvin, UK). The MTT test was performed with 3-(4-5 dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT) and DMSO, both from Sigma.
Methotrexate (MTX) chemotherapy is an active treatment in several malignancies, including head and neck, breast, and bone tumours, leukaemias and lymphomas (Jolivet et al., 1983) . High-dose MTX is followed by folinic acid (FA) rescue in order to increase the drug's therapeutic index. High-dose MTX with FA rescue has been administered in a wide variety of dosage schedules (Stoller et al., 1977; Bertino, 1981; Rosen et al., 1982; Evans et al., 1983; Jaffe et al., 1985) . Based on these recent studies, FA rescue appears to vary as a function of the dose used and the time of rescue initiation after the start of MTX (between 8 to 36 h). As stressed recently by Ackland and Schilsky (1987) , questions concerning the optimal application of FA rescue remain unsolved, particularly the interval between MTX and FA administration, and the dose and duration of FA rescue. This need is illustrated in the recent report by Browman et al. (1990) demonstrating in a randomised clinical trial that toxicity and the antitumour response were both decreased by FA when standard doses of MTX were used.
FA is a pharmaceutical preparation consisting of a 50-50 mixture of the natural I-FA and d-FA forms. Pharmacokinetic studies have established that I-FA and d-FA have considerably different blood kinetics; in particular, d-FA accumulation is due to the longer half-life of this form than the I-form (Straw et al., 1984; Newman et al., 1989) . This raises the question of the pharmacological role of the d-form, which interferes with intracellular activation of MTX by polyglutamation (Sato & Moran, 1984 (86 fLM) and 1-glutamine (2 mM). In brief, cells were grown in 96-well microtitration plates in their respective culture medium; 24 h later, they were exposed to MTX for 24 h. The respective initial cellular densities (Table I) were determined by a preliminary study in order to obtain optimal logarithmic growth. The MTX concentrations used (Table I) 168 h depending on the time required for the controls without drugs to reach 90% confluence (Table I) .
Evaluation of cytotoxicity The cytotoxic effects of MTX were assessed by the MTT semi-automated test (Carmichael et al., 1987; Twentyman & Luscombe, 1987) by FA were those derived from breast carcinomas; consequently, for these cell lines, the cut-off of 18-24 h was not as clear. For these cell lines a substantial reversal percentage was noted when FA was given at the same time as MTX and with a FA/MTX ratio of 0.01. The osteosarcoma cell lines presented an intermediary sensitivity to salvage by FA. The head and neck cell line CAL 27 and the lymphoblastoid cell line were the least sensitive to reversal of MTX cytotoxicity by FA; for these cell lines, an FA/MTX ratio of 1 was necessary to observe any appreciable reversal when both drugs were given at the same time. Considering the different FA/MTX ratios, and regardless of the interval between MTX and FA, a significant direct relationship was noted between this ratio and the recovery percentage (Table II) . The MTX concentration had a significant influence on the degree of reversal of MTX cytotoxicity for FA/MTX ratios of 0.01 and 0.1 (Table II) . In these cases, relatively more FA would have been required to achieve an equivalent rescue with increasing MTX concentrations. By contrast, for FA/MTX ratios of 1 and 10, the MTX concentrations used had no significant effect on the percentage of MTX cytotoxicity reversal.
For all of the experimental conditions tested, Figure 5 illustrates the correlation between cell survival in the presence of MTX-d,l-FA and in the presence of MTX-1-FA; the concentrations in 1-natural forms were identical in each pair. This figure reveals that the presence of an additive equimolar concentration of the d-form had no effect on the MTX salvage induced by the I-form. 'Friedman Rank analysis. 
I Discussion
The experimental conditions used tended to reduce the unavoidable differences between in vitro observations and in vivo treatment conditions into patients. This was achieved by the use of human tumour cell lines covering the spectrum of MTX-sensitive tumours (Jolivet et al., 1983) , by selection of a 24 h MTX exposure period and by using MTX and FA concentrations representative of the clinical context (Stoller et al., 1977; Straw et al., 1984; Parker et al., 1986; Milano et al., 1986; Schroder et al., 1987; Borsi & Moe, 1987; Schilsky et al., 1989) . Among the clinically relevant conclusions which can be drawn from the present study, the optimum time interval between MTX and FA appears to be around 18-24 h; a marked reduction in MTX cytotoxicity occurs during shorter intervals. This observation concurs well with the similar conclusions of a comparable study on human osteosarcoma cell lines (Diddens et al., 1987) and with the data reported by Sirotnak et al. (1978) (Stoller et al., 1979) . This finding may explain why patients treated by standard dose MTX plus FA rescue, exhibited a significantly lower response rate than those receiving only MTX, in a randomised placebo-controlled study (Browman et al., 1990) . For an equivalent MTX rescue, Pinedo et al. (1976) and Diddens et al. (1987) noted that proportionally more FA was required with higher MTX concentrations. Diddens et al. (1987) suggested that this metabolic feature might be due to a high production of MTX polyglutamate facilitated by high intracellular levels of MTX. Such observations were statistically confirmed in the present study on a larger number of cell lines. However, the effects of the MTX concentration on the percentage of cytotoxicity reversal by FA, at a given FA/MTX ratio, depended on the value of this ratio. Statistical significance was reached only for the lowest ratios (0.01, 0.1) and not for the highest ratios (1, 10). These observations could be explained by the fact that active membrane transport is exceeded at high MTX extracellular concentrations, and the drug passively enters tumour cells (Warren et al., 1978) . This unregulated influx should cause a disproportional intracellular competition between MTX and FA; only sufficiently high FA/MTX ratios could suppress such MTX dose-related effects.
Owing to its longer half-life, d-FA tends to accumulate more than 1-FA in treated patients (Straw et al., 1984; Newman et al., 1989) , and we thus decided to test the effects of the presence of an equimolar concentrations of d-FA on the I-FA MTX rescue capacity. An equimolar ratio between d-FA and I-FA is found between d-FA and active forms of FA during repeated oral doses of FA in treated patients (Schilsky et al., 1989) . The experimental conditions we used were thus also representative of the clinical context. Presence of the d-form had no influence on the MTX rescue capacity of the 1-form. Bertrand and Jolivet (1989) found that d-FA failed to interfere with cell growth support or enhancement of 5-FU cytotoxicity by the 1-isomer in CCRF-CEM cells in tissue culture experiments. Taken together these results suggest that, in current clinical indications of FA in oncology for MTX rescue or as a 5-FU cytotoxicity enhancer, the presence of the d-form is unlikely to have any significant clinical consequence. Controlled clinical trials comparing the effects of the administration of d,l-FA versus I-FA should provide more definitive data.
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